Immunic Inc. (IMUX), a clinical-stage biotechnology company developing small-molecule therapies for chronic inflammatory and autoimmune diseases, is gearing up for a key catalyst - and it all revolves around its lead drug candidate, Vidofludimus calcium.
Vidofludimus calcium is a small-molecule therapy designed to target multiple pathways driving neurodegeneration, including inflammation, viral activity, and direct neuronal damage, in the treatment of Multiple sclerosis.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com